S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
PRI   136.40 (+0.52%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
GILD   67.00 (-0.52%)
Log in

LON:MTPH - Midatech Pharma Share Price, Forecast & News

GBX 2.75
+0.05 (+1.85 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
2.63
Now: GBX 2.75
2.80
50-Day Range
2.60
MA: GBX 3.05
4
52-Week Range
2
Now: GBX 2.75
11.50
Volume162,657 shs
Average Volume61,863 shs
Market Capitalization£12.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1235-841575

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£1.84 million
Cash FlowGBX 2.09 per share
Book ValueGBX 6 per share

Profitability

Miscellaneous

Employees73
Market Cap£12.92 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MTPH and its competitors with MarketBeat's FREE daily newsletter.


Midatech Pharma (LON:MTPH) Frequently Asked Questions

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the London Stock Exchange (LON) under the ticker symbol "MTPH."

How were Midatech Pharma's earnings last quarter?

Midatech Pharma PLC (LON:MTPH) released its quarterly earnings results on Thursday, September, 28th. The company reported ($19.00) EPS for the quarter. The company had revenue of $3.02 million for the quarter. View Midatech Pharma's Earnings History.

Has Midatech Pharma been receiving favorable news coverage?

News coverage about MTPH stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Midatech Pharma earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Midatech Pharma.

Who are some of Midatech Pharma's key competitors?

What other stocks do shareholders of Midatech Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Midatech Pharma investors own include Barclays (BARC), Aldeyra Therapeutics (ALDX), Futura Medical (FUM), Lloyds Banking Group (LLOY), Pearson (PSON), Royal Mail (RMG), Telefonaktiebolaget LM Ericsson (ERIC), BAE Systems (BA), AstraZeneca (AZN) and Aviva (AV).

Who are Midatech Pharma's key executives?

Midatech Pharma's management team includes the folowing people:
  • Mr. Nicholas John Robbins-Cherry, CFO, Company Sec. & Director (Age 50)
  • Dr. Craig Richard Cook, CEO, COO & Director (Age 52)
  • Mr. Rob Rainey FCA MBA MA, Head of Corp. Devel.
  • Dr. Tim Sparey Ph.D., Chief Bus. Officer
  • Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP, Head of Manufacturing

How do I buy shares of Midatech Pharma?

Shares of MTPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Midatech Pharma's stock price today?

One share of MTPH stock can currently be purchased for approximately GBX 2.75.

How big of a company is Midatech Pharma?

Midatech Pharma has a market capitalization of £12.92 million and generates £1.84 million in revenue each year. Midatech Pharma employs 73 workers across the globe.View Additional Information About Midatech Pharma.

What is Midatech Pharma's official website?

The official website for Midatech Pharma is http://www.midatechpharma.com/.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is 65 Innovation Drive, Milton Park, ABINGDON, OX14 4RQ, United Kingdom. The company can be reached via phone at +44-1235-841575.


MarketBeat Community Rating for Midatech Pharma (LON MTPH)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Midatech Pharma and other stocks. Vote "Outperform" if you believe MTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel